Inhaled treprostinil for pulmonary hypertension
This article has no abstract so we have provided the first paragraph of the full text.
Inhaled iloprost was recently approved as a treatment for severe pulmonary arterial hypertension in Europe, Australia and the US, but inhalation sessions of up to approximately 2 h per day are time-consuming. Another prostacyclin analog, treprostinil, has a longer plasma half-life and might, therefore, require less frequent administration if inhaled; however, this drug has only been approved for intravenous or subcutaneous delivery.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
